Introduction: Pulmonary fibrosis (PF) causes progressive symptoms, worsening quality of life, and premature death. Interstitial lung abnormalities (ILAs) is a radiological definition for incidental findings in asymptomatic individuals involving >5% of lung parenchyma. The exact proportion of ILAs progressing into PF is yet to be elucidated. However, evidence of shared genetic abnormalities and risk factors suggests that some ILAs will progress into PF.

Aims: to consider healthcare professionals' (HCPs) views on screening for ILAs and early treatment models.

Methods: Through purposive sampling, 30 HCPs with > 3 years of experience are invited for a one-to-one semi-structured interview. Interviews are verbatim transcribed and analysed with thematic analysis.

Results: We present preliminary data from the first 23 HCP interviews: 13 physicians, 5 radiologists, 2 nurses, 2 pharmacists, 1 GP. There is agreement on the definition of PF and the conditions causing it. ILAs? key characteristics are incidental findings in asymptomatic patients, though there was no agreement on follow-up plans. A screening programme with CT scans may be designed for high-risk populations: first-degree relatives of PF patients, people with connective tissue diseases, occupational exposure, and ex-smokers. Active recruitment in primary care and national campaigns should be sought. There is disagreement about designing a clinical trial for ILAs due to the lack of data about the molecular pathway and progression. Drug side effects are a significant concern.

Conclusions: HCPs consider feasible a screening programme for ILAs. Further research is recommended to better phenotype ILAs before designing a clinical trial.